Table 2

APOE allele and genotype frequency in patients with DLB or AD, and healthy control individuals

GroupnAllele frequency (%)Genotypes (%)
ε2ε3ε4ε2/ε2ε2/ε3ε2/ε4ε3/ε3ε3/ε4ε4/ε4
DLB1565.162.832.10.64.54.541.040.49.0
F677.557.535.01.57.54.534.338.813.4
M893.466.829.80.02.24.546.141.65.6
AD5195.851.342.90.26.25.027.242.219.3
F3515.751.742.60.35.15.728.241.918.8
M1686.050.643.40.08.33.625.042.920.2
Healthy controls64310.675.014.40.616.33.656.820.42.3
F38810.275.514.30.515.73.657.220.92.1
M25511.274.314.50.817.33.556.119.62.7
  • No significant difference in APOE allele and genotype frequencies between the TrønderBrain and DemVest cohorts, so all DLB patients have been pooled to a single group.

  • The APOE ε4 allele was significantly increased in both the DLB (p<0.0005) and AD patient groups (p<0.0005) compared with healthy controls, and was more common in AD than DLB (p=0.004). Conversely, the APOE ε2 allele was reduced in the DLB (p=0.002) and AD (p<0.0005) patient groups compared with controls (Pearson's χ2 test).

  • AD, Alzheimer's disease DLB, dementia with Lewy bodies.